APO Research
Talk to an analyst

APO RESEARCH · REPORT

Muscle Relaxant Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Muscle Relaxant Drug Industry Research Report 2026

19 December 2025138 pages

Choose your research edition.

Industry ResearchMuscle Relaxant Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Muscle Relaxant Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Muscle Relaxant Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Muscle Relaxant Drug Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Muscle Relaxant Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Muscle Relaxant Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Muscle Relaxant Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Muscle Relaxant Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Muscle Relaxant Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Muscle Relaxant Drug include Amneal Pharmaceuticals LLC, Eisai, Endo Pharmaceuticals, lpsen Biopharmaceuticals,Inc., Mallinckrodt, Merz Pharmaceuticals,LLC., MetacelPharmaceuticals, LLC., ParPharmaceutical and SteriMax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Muscle Relaxant Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Muscle Relaxant Drug Market by Company

Amneal Pharmaceuticals LLC

Eisai

Endo Pharmaceuticals

lpsen Biopharmaceuticals,Inc.

Mallinckrodt

Merz Pharmaceuticals,LLC.

MetacelPharmaceuticals, LLC.

ParPharmaceutical

SteriMax

Vertical Pharmaceuticals

Pfizer

Eli Lilly and Company

Merck & Co., Inc.

Novartis AG,

Johnson & Johnson

TevaPharmaceuticals USA

Muscle Relaxant Drug Segment by Type

Centrally Acting Muscle Relaxants

Peripherally Acting Muscle Relaxants

Muscle Relaxant Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Muscle Relaxant Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Muscle Relaxant Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Muscle Relaxant Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Muscle Relaxant Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Muscle Relaxant Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Muscle Relaxant Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Muscle Relaxant Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Muscle Relaxant Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Muscle Relaxant Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Muscle Relaxant Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Muscle Relaxant Drug Revenue of Manufacturers (2021-2026) Table 9. Global Muscle Relaxant Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Muscle Relaxant Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Muscle Relaxant Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Muscle Relaxant Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Muscle Relaxant Drug, Product Type & Application Table 14. Global Muscle Relaxant Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Muscle Relaxant Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Amneal Pharmaceuticals LLC Company Information Table 19. Amneal Pharmaceuticals LLC Business Overview Table 20. Amneal Pharmaceuticals LLC Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Amneal Pharmaceuticals LLC Muscle Relaxant Drug Product Portfolio Table 22. Amneal Pharmaceuticals LLC Recent Developments Table 23. Eisai Company Information Table 24. Eisai Business Overview Table 25. Eisai Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Eisai Muscle Relaxant Drug Product Portfolio Table 27. Eisai Recent Developments Table 28. Endo Pharmaceuticals Company Information Table 29. Endo Pharmaceuticals Business Overview Table 30. Endo Pharmaceuticals Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Endo Pharmaceuticals Muscle Relaxant Drug Product Portfolio Table 32. Endo Pharmaceuticals Recent Developments Table 33. lpsen Biopharmaceuticals,Inc. Company Information Table 34. lpsen Biopharmaceuticals,Inc. Business Overview Table 35. lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Product Portfolio Table 37. lpsen Biopharmaceuticals,Inc. Recent Developments Table 38. Mallinckrodt Company Information Table 39. Mallinckrodt Business Overview Table 40. Mallinckrodt Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Mallinckrodt Muscle Relaxant Drug Product Portfolio Table 42. Mallinckrodt Recent Developments Table 43. Merz Pharmaceuticals,LLC. Company Information Table 44. Merz Pharmaceuticals,LLC. Business Overview Table 45. Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Product Portfolio Table 47. Merz Pharmaceuticals,LLC. Recent Developments Table 48. MetacelPharmaceuticals, LLC. Company Information Table 49. MetacelPharmaceuticals, LLC. Business Overview Table 50. MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Product Portfolio Table 52. MetacelPharmaceuticals, LLC. Recent Developments Table 53. ParPharmaceutical Company Information Table 54. ParPharmaceutical Business Overview Table 55. ParPharmaceutical Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. ParPharmaceutical Muscle Relaxant Drug Product Portfolio Table 57. ParPharmaceutical Recent Developments Table 58. SteriMax Company Information Table 59. SteriMax Business Overview Table 60. SteriMax Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. SteriMax Muscle Relaxant Drug Product Portfolio Table 62. SteriMax Recent Developments Table 63. Vertical Pharmaceuticals Company Information Table 64. Vertical Pharmaceuticals Business Overview Table 65. Vertical Pharmaceuticals Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Vertical Pharmaceuticals Muscle Relaxant Drug Product Portfolio Table 67. Vertical Pharmaceuticals Recent Developments Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Pfizer Muscle Relaxant Drug Product Portfolio Table 72. Pfizer Recent Developments Table 73. Eli Lilly and Company Company Information Table 74. Eli Lilly and Company Business Overview Table 75. Eli Lilly and Company Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Eli Lilly and Company Muscle Relaxant Drug Product Portfolio Table 77. Eli Lilly and Company Recent Developments Table 78. Merck & Co., Inc. Company Information Table 79. Merck & Co., Inc. Business Overview Table 80. Merck & Co., Inc. Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Merck & Co., Inc. Muscle Relaxant Drug Product Portfolio Table 82. Merck & Co., Inc. Recent Developments Table 83. Novartis AG, Company Information Table 84. Novartis AG, Business Overview Table 85. Novartis AG, Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Novartis AG, Muscle Relaxant Drug Product Portfolio Table 87. Novartis AG, Recent Developments Table 88. Johnson & Johnson Company Information Table 89. Johnson & Johnson Business Overview Table 90. Johnson & Johnson Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Johnson & Johnson Muscle Relaxant Drug Product Portfolio Table 92. Johnson & Johnson Recent Developments Table 93. TevaPharmaceuticals USA Company Information Table 94. TevaPharmaceuticals USA Business Overview Table 95. TevaPharmaceuticals USA Muscle Relaxant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. TevaPharmaceuticals USA Muscle Relaxant Drug Product Portfolio Table 97. TevaPharmaceuticals USA Recent Developments Table 98. Global Muscle Relaxant Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Muscle Relaxant Drug Sales by Region (2021-2026) & (K Units) Table 100. Global Muscle Relaxant Drug Sales Market Share by Region (2021-2026) Table 101. Global Muscle Relaxant Drug Sales by Region (2027-2032) & (K Units) Table 102. Global Muscle Relaxant Drug Sales Market Share by Region (2027-2032) Table 103. Global Muscle Relaxant Drug Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Muscle Relaxant Drug Revenue Market Share by Region (2021-2026) Table 105. Global Muscle Relaxant Drug Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Muscle Relaxant Drug Revenue Market Share by Region (2027-2032) Table 107. North America Muscle Relaxant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Muscle Relaxant Drug Sales by Country (2021-2026) & (K Units) Table 109. North America Muscle Relaxant Drug Sales by Country (2027-2032) & (K Units) Table 110. North America Muscle Relaxant Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Muscle Relaxant Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Muscle Relaxant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Muscle Relaxant Drug Sales by Country (2021-2026) & (K Units) Table 114. Europe Muscle Relaxant Drug Sales by Country (2027-2032) & (K Units) Table 115. Europe Muscle Relaxant Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Muscle Relaxant Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Muscle Relaxant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Muscle Relaxant Drug Sales by Country (2021-2026) & (K Units) Table 119. Asia Pacific Muscle Relaxant Drug Sales by Country (2027-2032) & (K Units) Table 120. Asia Pacific Muscle Relaxant Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Muscle Relaxant Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Muscle Relaxant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Muscle Relaxant Drug Sales by Country (2021-2026) & (K Units) Table 124. South America Muscle Relaxant Drug Sales by Country (2027-2032) & (K Units) Table 125. South America Muscle Relaxant Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Muscle Relaxant Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Muscle Relaxant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Muscle Relaxant Drug Sales by Country (2021-2026) & (K Units) Table 129. Middle East and Africa Muscle Relaxant Drug Sales by Country (2027-2032) & (K Units) Table 130. Middle East and Africa Muscle Relaxant Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Muscle Relaxant Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Muscle Relaxant Drug Sales by Type (2021-2026) & (K Units) Table 133. Global Muscle Relaxant Drug Sales by Type (2027-2032) & (K Units) Table 134. Global Muscle Relaxant Drug Sales Market Share by Type (2021-2026) Table 135. Global Muscle Relaxant Drug Sales Market Share by Type (2027-2032) Table 136. Global Muscle Relaxant Drug Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Muscle Relaxant Drug Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Muscle Relaxant Drug Revenue Market Share by Type (2021-2026) Table 139. Global Muscle Relaxant Drug Revenue Market Share by Type (2027-2032) Table 140. Global Muscle Relaxant Drug Price by Type (2021-2026) & (US$/Unit) Table 141. Global Muscle Relaxant Drug Price by Type (2027-2032) & (US$/Unit) Table 142. Global Muscle Relaxant Drug Sales by Application (2021-2026) & (K Units) Table 143. Global Muscle Relaxant Drug Sales by Application (2027-2032) & (K Units) Table 144. Global Muscle Relaxant Drug Sales Market Share by Application (2021-2026) Table 145. Global Muscle Relaxant Drug Sales Market Share by Application (2027-2032) Table 146. Global Muscle Relaxant Drug Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Muscle Relaxant Drug Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Muscle Relaxant Drug Revenue Market Share by Application (2021-2026) Table 149. Global Muscle Relaxant Drug Revenue Market Share by Application (2027-2032) Table 150. Global Muscle Relaxant Drug Price by Application (2021-2026) & (US$/Unit) Table 151. Global Muscle Relaxant Drug Price by Application (2027-2032) & (US$/Unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Muscle Relaxant Drug Distributors List Table 155. Muscle Relaxant Drug Customers List Table 156. Muscle Relaxant Drug Industry Trends Table 157. Muscle Relaxant Drug Industry Drivers Table 158. Muscle Relaxant Drug Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Muscle Relaxant Drug Product Image Figure 5. Global Muscle Relaxant Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Muscle Relaxant Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Muscle Relaxant Drug Sales (2021-2032) & (K Units) Figure 8. Global Muscle Relaxant Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Centrally Acting Muscle Relaxants Product Image Figure 10. Peripherally Acting Muscle Relaxants Product Image Figure 11. Retail Pharmacy Product Image Figure 12. Online Pharmacy Product Image Figure 13. Hospital Pharmacy Product Image Figure 14. Global Muscle Relaxant Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Muscle Relaxant Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Muscle Relaxant Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Muscle Relaxant Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Muscle Relaxant Drug Sales by Region in 2025 Figure 20. Global Muscle Relaxant Drug Revenue by Region in 2025 Figure 21. North America Muscle Relaxant Drug Market Size by Country in 2025 Figure 22. North America Muscle Relaxant Drug Sales Market Share by Country (2021-2032) Figure 23. North America Muscle Relaxant Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Muscle Relaxant Drug Market Size by Country in 2025 Figure 27. Europe Muscle Relaxant Drug Sales Market Share by Country (2021-2032) Figure 28. Europe Muscle Relaxant Drug Revenue Market Share by Country (2021-2032) Figure 29. Germany Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Nordic Countries Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Muscle Relaxant Drug Market Size by Country in 2025 Figure 36. Asia Pacific Muscle Relaxant Drug Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Muscle Relaxant Drug Revenue Market Share by Country (2021-2032) Figure 38. China Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Muscle Relaxant Drug Market Size by Country in 2025 Figure 47. South America Muscle Relaxant Drug Sales Market Share by Country (2021-2032) Figure 48. South America Muscle Relaxant Drug Revenue Market Share by Country (2021-2032) Figure 49. Mexico Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Colombia Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Muscle Relaxant Drug Market Size by Country in 2025 Figure 54. Middle East and Africa Muscle Relaxant Drug Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Muscle Relaxant Drug Revenue Market Share by Country (2021-2032) Figure 56. Turkey Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Muscle Relaxant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Muscle Relaxant Drug Sales Market Share by Type (2021-2032) Figure 60. Global Muscle Relaxant Drug Revenue Market Share by Type (2021-2032) Figure 61. Global Muscle Relaxant Drug Price (US$/Unit) by Type (2021-2032) Figure 62. Global Muscle Relaxant Drug Sales Market Share by Application (2021-2032) Figure 63. Global Muscle Relaxant Drug Revenue Market Share by Application (2021-2032) Figure 64. Global Muscle Relaxant Drug Price (US$/Unit) by Application (2021-2032) Figure 65. Muscle Relaxant Drug Value Chain Figure 66. Muscle Relaxant Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Muscle Relaxant Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Centrally Acting Muscle Relaxants
  • Peripherally Acting Muscle Relaxants
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Amneal Pharmaceuticals LLC
  • Eisai
  • Endo Pharmaceuticals
  • lpsen Biopharmaceuticals,Inc.
  • Mallinckrodt
  • Merz Pharmaceuticals,LLC.
  • MetacelPharmaceuticals, LLC.
  • ParPharmaceutical
  • SteriMax
  • Vertical Pharmaceuticals
  • Pfizer
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG,
  • Johnson & Johnson
  • TevaPharmaceuticals USA

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Muscle Relaxant Drug Market Size (2021-2032)
  4. 2.2.2 Global Muscle Relaxant Drug Sales (2021-2032)
  5. 2.2.3 Global Muscle Relaxant Drug Market Average Price (2021-2032)
  6. 2.3 Muscle Relaxant Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Centrally Acting Muscle Relaxants
  9. 2.3.3 Peripherally Acting Muscle Relaxants
  10. 2.4 Muscle Relaxant Drug by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Retail Pharmacy
  13. 2.4.3 Online Pharmacy
  14. 2.4.4 Hospital Pharmacy
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Muscle Relaxant Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Muscle Relaxant Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Muscle Relaxant Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Muscle Relaxant Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Muscle Relaxant Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Muscle Relaxant Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Muscle Relaxant Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Muscle Relaxant Drug, Established Date
  9. 3.9 Global Muscle Relaxant Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Amneal Pharmaceuticals LLC
  2. 4.1.1 Amneal Pharmaceuticals LLC Company Information
  3. 4.1.2 Amneal Pharmaceuticals LLC Business Overview
  4. 4.1.3 Amneal Pharmaceuticals LLC Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Amneal Pharmaceuticals LLC Muscle Relaxant Drug Product Portfolio
  6. 4.1.5 Amneal Pharmaceuticals LLC Recent Developments
  7. 4.2 Eisai
  8. 4.2.1 Eisai Company Information
  9. 4.2.2 Eisai Business Overview
  10. 4.2.3 Eisai Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Eisai Muscle Relaxant Drug Product Portfolio
  12. 4.2.5 Eisai Recent Developments
  13. 4.3 Endo Pharmaceuticals
  14. 4.3.1 Endo Pharmaceuticals Company Information
  15. 4.3.2 Endo Pharmaceuticals Business Overview
  16. 4.3.3 Endo Pharmaceuticals Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Endo Pharmaceuticals Muscle Relaxant Drug Product Portfolio
  18. 4.3.5 Endo Pharmaceuticals Recent Developments
  19. 4.4 lpsen Biopharmaceuticals,Inc.
  20. 4.4.1 lpsen Biopharmaceuticals,Inc. Company Information
  21. 4.4.2 lpsen Biopharmaceuticals,Inc. Business Overview
  22. 4.4.3 lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Product Portfolio
  24. 4.4.5 lpsen Biopharmaceuticals,Inc. Recent Developments
  25. 4.5 Mallinckrodt
  26. 4.5.1 Mallinckrodt Company Information
  27. 4.5.2 Mallinckrodt Business Overview
  28. 4.5.3 Mallinckrodt Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mallinckrodt Muscle Relaxant Drug Product Portfolio
  30. 4.5.5 Mallinckrodt Recent Developments
  31. 4.6 Merz Pharmaceuticals,LLC.
  32. 4.6.1 Merz Pharmaceuticals,LLC. Company Information
  33. 4.6.2 Merz Pharmaceuticals,LLC. Business Overview
  34. 4.6.3 Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Product Portfolio
  36. 4.6.5 Merz Pharmaceuticals,LLC. Recent Developments
  37. 4.7 MetacelPharmaceuticals, LLC.
  38. 4.7.1 MetacelPharmaceuticals, LLC. Company Information
  39. 4.7.2 MetacelPharmaceuticals, LLC. Business Overview
  40. 4.7.3 MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Product Portfolio
  42. 4.7.5 MetacelPharmaceuticals, LLC. Recent Developments
  43. 4.8 ParPharmaceutical
  44. 4.8.1 ParPharmaceutical Company Information
  45. 4.8.2 ParPharmaceutical Business Overview
  46. 4.8.3 ParPharmaceutical Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 ParPharmaceutical Muscle Relaxant Drug Product Portfolio
  48. 4.8.5 ParPharmaceutical Recent Developments
  49. 4.9 SteriMax
  50. 4.9.1 SteriMax Company Information
  51. 4.9.2 SteriMax Business Overview
  52. 4.9.3 SteriMax Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 SteriMax Muscle Relaxant Drug Product Portfolio
  54. 4.9.5 SteriMax Recent Developments
  55. 4.10 Vertical Pharmaceuticals
  56. 4.10.1 Vertical Pharmaceuticals Company Information
  57. 4.10.2 Vertical Pharmaceuticals Business Overview
  58. 4.10.3 Vertical Pharmaceuticals Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Vertical Pharmaceuticals Muscle Relaxant Drug Product Portfolio
  60. 4.10.5 Vertical Pharmaceuticals Recent Developments
  61. 4.11 Pfizer
  62. 4.11.1 Pfizer Company Information
  63. 4.11.2 Pfizer Business Overview
  64. 4.11.3 Pfizer Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Pfizer Muscle Relaxant Drug Product Portfolio
  66. 4.11.5 Pfizer Recent Developments
  67. 4.12 Eli Lilly and Company
  68. 4.12.1 Eli Lilly and Company Company Information
  69. 4.12.2 Eli Lilly and Company Business Overview
  70. 4.12.3 Eli Lilly and Company Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Eli Lilly and Company Muscle Relaxant Drug Product Portfolio
  72. 4.12.5 Eli Lilly and Company Recent Developments
  73. 4.13 Merck & Co., Inc.
  74. 4.13.1 Merck & Co., Inc. Company Information
  75. 4.13.2 Merck & Co., Inc. Business Overview
  76. 4.13.3 Merck & Co., Inc. Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Merck & Co., Inc. Muscle Relaxant Drug Product Portfolio
  78. 4.13.5 Merck & Co., Inc. Recent Developments
  79. 4.14 Novartis AG,
  80. 4.14.1 Novartis AG, Company Information
  81. 4.14.2 Novartis AG, Business Overview
  82. 4.14.3 Novartis AG, Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Novartis AG, Muscle Relaxant Drug Product Portfolio
  84. 4.14.5 Novartis AG, Recent Developments
  85. 4.15 Johnson & Johnson
  86. 4.15.1 Johnson & Johnson Company Information
  87. 4.15.2 Johnson & Johnson Business Overview
  88. 4.15.3 Johnson & Johnson Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Johnson & Johnson Muscle Relaxant Drug Product Portfolio
  90. 4.15.5 Johnson & Johnson Recent Developments
  91. 4.16 TevaPharmaceuticals USA
  92. 4.16.1 TevaPharmaceuticals USA Company Information
  93. 4.16.2 TevaPharmaceuticals USA Business Overview
  94. 4.16.3 TevaPharmaceuticals USA Muscle Relaxant Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 TevaPharmaceuticals USA Muscle Relaxant Drug Product Portfolio
  96. 4.16.5 TevaPharmaceuticals USA Recent Developments
5 Global Muscle Relaxant Drug Market Scenario by Region
  1. 5.1 Global Muscle Relaxant Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Muscle Relaxant Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Muscle Relaxant Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Muscle Relaxant Drug Sales by Region: 2027-2032
  5. 5.3 Global Muscle Relaxant Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Muscle Relaxant Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Muscle Relaxant Drug Revenue by Region: 2027-2032
  8. 5.4 North America Muscle Relaxant Drug Market Facts & Figures by Country
  9. 5.4.1 North America Muscle Relaxant Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Muscle Relaxant Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Muscle Relaxant Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Muscle Relaxant Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Muscle Relaxant Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Muscle Relaxant Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Muscle Relaxant Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Muscle Relaxant Drug Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Muscle Relaxant Drug Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Muscle Relaxant Drug Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Muscle Relaxant Drug Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Muscle Relaxant Drug Market Facts & Figures by Country
  36. 5.7.1 South America Muscle Relaxant Drug Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Muscle Relaxant Drug Sales by Country (2021-2032)
  38. 5.7.3 South America Muscle Relaxant Drug Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.7.7 Colombia
  43. 5.8 Middle East and Africa Muscle Relaxant Drug Market Facts & Figures by Country
  44. 5.8.1 Middle East and Africa Muscle Relaxant Drug Market Size by Country: 2021 VS 2025 VS 2032
  45. 5.8.2 Middle East and Africa Muscle Relaxant Drug Sales by Country (2021-2032)
  46. 5.8.3 Middle East and Africa Muscle Relaxant Drug Revenue by Country (2021-2032)
  47. 5.8.4 Turkey
  48. 5.8.5 Saudi Arabia
  49. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Muscle Relaxant Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Muscle Relaxant Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Muscle Relaxant Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Muscle Relaxant Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Muscle Relaxant Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Muscle Relaxant Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Muscle Relaxant Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Muscle Relaxant Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Muscle Relaxant Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Muscle Relaxant Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Muscle Relaxant Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Muscle Relaxant Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Muscle Relaxant Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Muscle Relaxant Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Muscle Relaxant Drug Value Chain Analysis
  2. 8.1.1 Muscle Relaxant Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Muscle Relaxant Drug Production Mode & Process
  5. 8.2 Muscle Relaxant Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Muscle Relaxant Drug Distributors
  8. 8.2.3 Muscle Relaxant Drug Customers
9 Global Muscle Relaxant Drug Analyzing Market Dynamics
  1. 9.1 Muscle Relaxant Drug Industry Trends
  2. 9.2 Muscle Relaxant Drug Industry Drivers
  3. 9.3 Muscle Relaxant Drug Industry Opportunities and Challenges
  4. 9.4 Muscle Relaxant Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst